Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Brief: Celltrion Presents Efficacy And Safety Data For Potential COVID-19 Treatment Candidate CT-P59 In Patients With Mild Symptoms

Nov 5 (Reuters) - Celltrion:
    * CELLTRION PRESENTS EFFICACY AND SAFETY DATA FOR POTENTIAL
COVID-19 TREATMENT CANDIDATE CT-P59 IN PATIENTS WITH MILD
SYMPTOMS
    * CELLTRION - TRIAL RESULTS INDICATE TREATMENT WITH CT-P59
RESULTED IN AT LEAST 44% FASTER RECOVERY TIME WHEN COMPARED WITH
PLACEBO
    * CELLTRION - NO PATIENTS TREATED WITH CT-P59 IN STUDY HAVE
SO FAR
REQUIRED HOSPITALISATION OR OTHER ANTIVIRAL THERAPY AS A RESULT
OF COVID-19
    * CELLTRION- CT-P59 WAS WELL TOLERATED WITH NO CLINICALLY
SIGNIFICANT SAFETY ISSUES SEEN IN STUDY POPULATION
    * CELLTRION - ANNOUNCED RESULTS FROM ONGOING PHASE I
CLINICAL
TRIAL OF CT-P59, AN ANTI-COVID-19 MONOCLONAL ANTIBODY TREATMENT
CANDIDATE

Source text for Eikon:  ID:nBwVGxwla 
Further company coverage:  068270.KS   091990.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Celltrion Healthcare Co

See all news